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Footnote page: 
Abbreviations: 
ACR: Acute cellular rejection 
ALP: Alkaline phosphatise 
ALT: Alanine aminotransferase 
AST: Aspartate aminotransferase 
AUC0-12: Individual area under the whole blood or intracellular concentration–time curve from 0 to 12 
hours 
AUC0-12CNA: Individual area under the intracellular calcineurin activity curve from 0 to 12 hours 
Cmax: Maximal concentration, peak concentratio 
C12h: Trough concentration 
EC50: Concentration which decreases maximal effect by a half 
LC-MS/MS: Liquid chromatography tandem mass spectrometry 
PBMC: Peripheral blood mononuclear cells 
SEM: Standard error of the mean 
SD: Standard deviation 
TAC: Tacrolimus 
TDM: Therapeutic drug monitoring 
WB: Whole blood 
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Abstract: 
Objectives: Despite improvements in patient management and extensive use of 
therapeutic drug monitoring (TDM), the rate of acute cellular rejection (ACR) remains 
high in patients treated with tacrolimus (TAC). Moreover, some patients experienced 
ACR while their whole-blood (WB) concentrations were maintained within the 
therapeutic range meaning that TDM in WB misrepresents the drug effect. Thus, 
monitoring TAC directly inside of its effect compartment (intracellular concentrations) 
or monitoring directly the inhibitory effect on the target protein (calcineurin activity) 
could be more relevant. The aim of the present study was to explore, in 10 de novo 
liver transplant recipients, the relationship between TAC whole-blood concentrations, 
TAC intracellular concentrations and TAC-induced intracellular calcineurin inhibition 
at day 1 and day 7 after treatment initiation. 
Design & Methods: Prospective monocentric observational pharmacokinetic (WB 
and intracellular concentrations) – pharmacodynamic (calcineurin activity) study. 
Results: Full intracellular TAC pharmacokinetic as well as calcineurin activity steady-
state profiles are presented in the study. The main result of this study is the lack of 
relationship between TAC pharmacokinetics (WB and leukocytes) and calcineurin 
activity in leukocytes at day 1 and day 7 after the graft implantation. 
Conclusions: Drug monitoring of TAC intracellular concentrations and determination 
of the calcineurin activity are among future potential biomarkers of acute rejection in 
transplant recipients. A better knowledge of the relationship between TAC whole 
blood and intracellular concentrations and calcineurin activity appears necessary 
before planning clinical trials to evaluate their potential interest as predictive 
biomarkers. 
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Keywords: Immunosuppressive drugs, therapeutic drug monitoring, peripheral 
blood mononuclear cells, intracellular, calcineurin 
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1. Introduction: 
 
Tacrolimus (TAC), a calcineurin inhibitor, is widely used to prevent acute cellular 
rejection (ACR) after liver transplantation [1]. Despite improvements and research 
efforts in immunosuppression, the rate of ACR remains frequent, varying from 8% up 
to 30% during the first two years following transplantation [2,3]. Variability in TAC 
pharmacokinetics might at least partially contribute to liver graft rejection in recipients 
under TAC. Therapeutic drug monitoring (TDM) based on TAC whole blood 
concentration assessment is commonly used as a marker to prevent ACR. Besides, 
a pharmacogenetic approach [4] or a dose individualization based on Bayesian 
models [5,6] or bottom-up approach [7] may be helpful to further optimize the 
individualization of TAC dosing in liver transplant recipients. However, it is still 
uncertain whether these two latter approaches have a significant impact on clinical 
outcome [8,9]. Finally, some patients continue to experience ACR whereas their TAC 
whole blood concentrations are within the recommended therapeutic range. Although 
the mechanism underlying such a phenomenon remains unexplained, this suggests 
that TAC whole blood concentration does not necessarily correlate with the 
pharmacological effect of TAC on intralymphocyte calcineurin activity. In this context, 
measurement of intralymphocyte TAC concentrations and/or a pharmacodynamic 
approach may be helpful to address this issue. 
 
Assaying intralymphocyte TAC concentrations has been proposed to be of possible 
interest in evaluating the effects of TAC [10,11]. Indeed, intra- and inter-variability in 
TAC binding to erythrocytes and lipoproteins can significantly influence the diffusion 
of TAC in lymphocytes from liver transplant recipients [12], especially during the first 
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two weeks following the graft implantation. Additionally, efflux-drug transporters such 
as ABCB1 (P-glycoprotein, P-gp) are expressed on the lymphocytes’ membrane [13]. 
TAC is known to be a substrate of ABCB1, which counter-transports TAC out of 
lymphocytes and back into the whole blood compartment. Therefore, the expression 
level of ABCB1 can impact TAC disposition in lymphocytes [14], especially in the 
presence of genetic polymorphisms and/or comedication which can cause an 
increase or decrease in ABCB1 activity on the membrane. Overall, these different 
factors contribute to the intra-and inter-individual variability in TAC disposition in 
lymphocytes. In this context, intralymphocyte TAC concentration could be a better 
surrogate marker than TAC whole blood concentration to reflect the 
pharmacodynamic effect of TAC.   
  
Finally, calcineurin activity is considered as one of the most relevant 
pharmacodynamic biomarkers because it directly reflects the pharmacological effect 
of TAC on its target [15]. Different investigations carried out in liver transplant 
recipients treated with TAC have shown that calcineurin activity in peripheral blood 
mononuclear cells (PBMC) was increased before ACR [16–18]. Despite these 
promising results, the monitoring of calcineurin activity remains difficult in daily 
clinical practice for analytical and sample preparation reasons [19].  
To our best knowledge, no work has attempted to describe the relationship between 
TAC whole-blood concentrations, TAC intracellular concentrations and TAC-induced 
intracellular calcineurin inhibition.   
In this context, the aim of the present study was to explore this relationship in 10 de 
novo liver transplant recipients treated with TAC at day 1 and day 7 after graft 
implantation and investigate if these assays can be conducted on a routine mode. 
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2. Materials and Methods: 
2.1 Patients and data collection: 
Ten de novo liver transplant recipients (nine men and one woman) were included in 
the present study. Seven patients were transplanted because of alcoholic cirrhosis, 
two patients because of alcoholic and metabolic cirrhosis and one patient because of 
alcoholic cirrhosis and hepatocellular carcinoma. All patients were involved in the 
clinical trial "Pharmacogenetic study of tacrolimus in hepatic transplant (CYPTAC’H)" 
(Clinicaltrials.gov identifier: NCT01388387). Caucasian patients over 18 years of age 
treated with TAC and who gave their written consent were included in the study. The 
investigational review board “Comité de Protection des Personnes – Ouest V” 
approved the study protocol; all patients provided written informed consent and 
approved the sampling and pharmacokinetic/pharmacodynamic analysis in 
compliance with the ethical principles of the revised Declaration of Helsinki (2008) 
and with French regulations. Patients with highly active antiretroviral therapy or with 
legal guardianship or deprived of freedom were not eligible for the study. 
TAC dose, haematocrit, serum protein, albumin, creatinine, total and conjugated 
bilirubin, AST, ALT and ALP and creatinine clearance were collected or calculated on 
the day of blood sampling. 
Patients were monitored for the first 6 months after transplantation with particular 
attention given to the occurrence of acute rejection. 
 
2.2 Immunosuppression protocol: 
TAC treatment was started either at 8:00 AM or 8:00 PM, depending on the time the 
surgical procedure was completed. The day of the first administration determined the 
first day of the study. Patients received initially a dose of 0.04 to 0.05 mg/kg per 
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12hrs calculated based on the ideal body weight or a dose of 0.02 to 0.03 mg/kg per 
12hrs calculated based on ideal body weight in case of concomitant administration of 
fluconazole prophylaxis. The subsequent doses were adapted to maintain trough 
TAC whole-blood concentrations between 6 and 10 ng/mL, as recently suggested 
[20]. From day 1 post-transplantation, patients concomitantly received oral 
mycophenolate mofetil 1.5 g twice daily and 20 mg of prednisone once daily. They 
also received a 500 mg methylprednisolone infusion as an induction and one other 
500 mg infusion at portal vein clamp removal. 
 
2.3 Blood sampling and cell separation  
On their first day of treatment and between the seventh and the tenth day of 
treatment, each patient underwent complete TAC pharmacokinetics. Five millilitres of 
peripheral venous blood were collected in EDTA tubes 0, 20, 40, 60, 120, 180, 240, 
360, 540 and 720 minutes after the morning oral dose of TAC (Prograf®). Samples 
were stored at 4°C until cells were separated. According to the literature, blood 
samples could be stored at 4°C up to 48 hours after the blood collection [21]. Cell 
separation was achieved using a Unisep U-02 device for density gradient separation 
of PBMC provided by Novamed© (Jerusalem, Israel) according to previously 
published procedures [22]. Blood was diluted with RPMI-glutamate (v/v) (Novamed©, 
Jerusalem, Israel), then centrifuged at 1200 G (without brake) during 20 minutes at 
room temperature (RT). The cell layer was collected with a pipette, washed twice 
with RPMI-glutamate and then centrifuged at 250 G during 10 minutes at 4°C. The 
washing procedure was performed twice. Cell counting was performed on a FC500 
(Beckman Coulter, Pasadena, CA, USA) according to previously published works 
[23,24]. Briefly, 50 μL of cells were incubated with 10 μL of CytoDiff© antibody 
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cocktail (Beckman Coulter) at RT during 15 min. Then, 500 μL of the “fix-and-lyse” 
mix (Versalyse + IOTest3, Beckman Coulter, Pasadena, CA, USA) were added and 
the sample was incubated at RT during 15 minutes. Finally, 50 μL of flowcount beads 
(Beckman Coulter, Pasadena, CA, USA) were added to calibrate the count.   
Because of granulocyte contamination during cell separation, all analyses were 
expressed for 1 million white blood cells. High contamination by granulocytes has 
already been described in intensive care unit patients with sepsis phase as well as in 
autoimmune diseases such as systemic lupus erythematosus [25],[26]. The cell pellet 
was then split in aliquots (5x105 cells each) dedicated to intracellular TAC 
concentration and calcineurin activity assays.  
 
2.4 Assessment of whole blood and intracellular TAC concentrations  
TAC was measured in whole blood using a validated liquid chromatography tandem 
mass spectrometry (LC-MS/MS) method. The accuracy of our method was ensured 
by participation in the Tacrolimus Proficiency Testing Scheme provided by the 
Cardiac and Vascular Sciences Analytic Unit of St. George’s Hospital Medical School 
(D. Holt, London, United Kingdom).   
Intracellular TAC concentration was assayed using a validated LC-MS/MS method 
adapted from previously published methods [22,27]. The intra-day coefficients of 
variation for TAC controls (50 and 200 pg/million PBMCs) were respectively 8.6 and 
9.0%. Coefficients of variation of inter-day analysis of TAC controls (50 and 200 
pg/million PBMC) were respectively 2.8 and 8.8%. 
 
2.5 Calcineurin activity assay 
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Calcineurin activity was determined by using high-performance liquid 
chromatography with ultra-violet detection as previously described [21].  The peptide 
used, D-L-D-V-P-I-P-G-R-F-D-R-R-V-S-V-A-A-E, is a partial sequence corresponding 
to the RII subunit of cAMP-dependent protein kinase. The protein phosphatase 2B 
(PP2B) substrate was obtained from Bachem (Bubendorf, Switzerland, >98% purity). 
Briefly, cells were resuspended in 20μl of lysis buffer (1M Tris-HCl, pH 8.0, 1M KCl, 
Nomidet 40 and tween 20). After a freeze-thaw cycle, lysates were mixed with 
analysis buffer (50 mM Tris-HCl, pH 7.0, 0.1 M EGTA, 0.5 mM dithiothreitol, 1 mM 
MnCl2, 0.3 mg/mL bovine serum albumin, 0.1 mM EGTA, 1 mM CaCl2 ,0.1 μM 
calmodulin, 500 nM okadaic acid). After sample incubation (15 minutes, 30°C), the 
reaction was initiated with the addition of phosphorylated peptides. Aliquots (50μl) 
were sampled at 5 and 10 minutes, and the enzymatic reaction was stopped with 20 
μL of perchloric acid 0.5%. A 50 μL aliquot was injected into the chromatographic 
system. Calcineurin activity was expressed as picomoles of dephosphorylated 
peptides per minute per 106 cells. The intra-day coefficients of variation for quality 
control for calcineurin activity (1428 and 2856 pmol) were respectively 1.0 and 2.1%. 
Accuracy was shown to be good with an average percentage of less than 98.4% 
(range 96.7–104.5) for the two quality controls. During the validation of analytical 
method, the method showed a good within-day precision (CV = 13.3%) including all 
the steps from blood collection to CNA activity assay by using liquid chromatography 
[21]. 
 
2.6 Statistical analysis 
The demographic and biological characteristics of the study cohort are presented as 
mean +/- standard deviation (SD). Creatinine clearance was estimated using the 
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Modification of Diet in Renal Disease formula [28]. The results of pharmacokinetic 
and pharmacodynamic data are expressed as mean +/- standard error of the mean 
(SEM). Individual area under the whole blood or intracellular TAC concentration–time 
curve from 0 to 12 hours (AUC0-12) was calculated according to the trapezoidal 
formula. This latter was also used to determine AUC0-12 for calcineurin activity (AUC0-
12CNA). The ratio TAC intracellular AUC0-12 over TAC whole-blood AUC0-12 on day 1 
and day 7 was calculated for each patient assuming that mean cell volume was 200 
femtoliters [29,30]. Using a mean volume of 200 femtoliters allows us to compare 
data in blood and within cells on a mass/volume point of view even if it imprecisely 
reflects the exact volume of the different population cells.  
Changes in AUC0-12CNA between day 1 and day 7 were also calculated for each 
patient by dividing the value of AUC0-12CNA on day 7 by the value of AUC0-12CNA on 
day 1. Whole blood, intracellular and calcineurin activity AUCs were compared 
between day 1 and day 7 using a paired Wilcoxon test. 
The relationships between TAC whole-blood AUC0-12, TAC intracellular AUC0-12 and 
AUC0-12CNA were tested out using the Spearman correlation test. 
All tests were two-sided, and they were considered significant when p-values were < 
0.05. Computations were performed using the SAS V9 statistical package (SAS 
institute, Cary, NC). 
 
3. Results: 
3.1 Patients’ characteristics 
Table 1 presents the baseline demographic and clinical data of the 10 de novo liver 
transplant recipients included in the study.  Biological parameters of patients at day 1 
and day 7 after graft implantation are summarized in Table 2.  
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3.2 TAC blood and intracellular pharmacokinetics  
Pharmacokinetic parameters for TAC at day 1 and day 7 after graft implantation are 
summarized in Table 3. In whole blood, TAC maximum concentration (Cmax) reached 
13.0 ± 9.6 ng/mL at 180 minutes on day 1 and 8.8 ± 5.0 ng/mL at 60 minutes on day 
7 (Figure 1). TAC trough concentrations (C12h) were 6.9 ± 3.1 ng/mL and 5.4 ± 3.1 
ng/mL on day 1 and day 7 respectively. Corresponding areas under the curve over 
the administration period (AUC0-12) were 111.8 ± 65.9 ng.h/mL and 81.2 ± 37.2 
ng.h/mL, respectively.  
For intracellular pharmacokinetics, mean Cmax reached 116.9 ± 114.7 pg/million 
leukocytes at 180 minutes on day 1 and 68.3 ± 48.9 pg/million leukocytes at 360 
minutes on day 7 (Figure 2). C12h were 71.3 ± 78.5 and 39.5 ± 38.8 pg/million 
leukocytes at day 1 and 7, respectively. AUC0-12 were 909.2 ± 903.7 pg.h/million 
leukocytes and 673.0 ± 603.0 pg.h/million leukocytes.  
The ratio TAC intracellular AUC0-12 over TAC whole-blood AUC0-12 presented a large 
variability at day 1 (5.2 to 70, mean 40.3 ± 23.3) and day 7 (8.0 to 114.8, mean 49.3 
± 23.3) 
 
3.3 TAC pharmacodynamics 
Figure 3 presents the time course of calcineurin activity in leukocytes at day 1 and 
day 7 after transplantation. At day 1, calcineurin activity changed in parallel with both 
whole blood and intracellular TAC concentrations. Thus, the time to achieve the 
mean maximum calcineurin inhibition (38 ± 16%) was close to that for maximum TAC 
whole blood and intracellular concentrations. At day 7, the mean calcineurin activity 
over the dosing interval was unchanged, within +/- 15%.      
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Mean AUC0-12CNA at day 1 and day 7 were not statistically different (AUC0-12CNA = 
404.2 ± 251.1 vs 472.8 ± 382.9 pmol/min/106 leukocytes, respectively; p=0.95). 
Overall, mean variation in AUC0-12CNA between day 1 and day 7 was 1.17 ± 0.65.  
 
3.4 PK-PD relationship 
A correlation between the whole blood TAC AUC0-12 and the intracellular TAC AUC0-
12 was observed at day 1 (rho= 0.69; p = 0.04) but not at day 7 (p = 0.75) (Figure 4). 
No correlation was found between whole blood TAC AUC0-12 and AUC0-12CNA at day 1 
(p = 0.92) and day 7 (p = 0.10) either between intracellular TAC AUC0-12 and AUC0-
12CNA at day 1 (p = 0.71) and day 7 (p = 0.88) (Figure 5). 
No difference could be found between day 1 and day 7 in whole blood AUC0-12 (p = 
0.25), intracellular AUC0-12 (p = 0.38), TAC diffusion ratio into leukocytes (p = 1.00), 
or AUC0-12CNA (p = 0.74). 
 
3.5 Clinical outcome 
One patient experienced an ACR during the study. The onset of this acute rejection 
was 17 days after the surgical procedure. This patient had TAC whole-blood AUC0-12 
at day 1 and day 7 (81.3 ng.h/mL and 70.0 ng.h/mL, respectively) close to the mean 
of the patient study on day 7. In contrast, his intracellular TAC AUC0-12 at day 1 and 
day 7 (186.2 pg.h/million leukocytes and 112.2 pg.h/million leukocytes, respectively) 
was approximately 4-fold lower than the mean AUC0-12 of the other patients. He also 
presented the lowest ratio TAC intracellular AUC0-12 over TAC whole-blood AUC0-12 at 
day 7 (8.0, study mean 49.3 ± 45.6). Finally, his AUC0-12CNA significantly increased 
from 90.7 pmol/min/106 leukocytes at day 1 to 189.5 pmol/min/106 leukocytes at day 
7. The change in AUC0-12CNA between day 1 and day 7 was 2.09 for this patient 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
14 
(mean change for all patients was 1.17 ± 0.65), that was the largest increase in the 
patient study. 
 
  
4. Discussion: 
Different investigations carried out in liver transplant recipients have already 
investigated the relationship between TAC whole blood concentrations and 
calcineurin activity in PBMC [16,17,31–33] or between concentrations of TAC in 
whole blood and PBMC [10,14,34]. To our best knowledge, the present study is the 
first to study both the pharmacokinetics of TAC in whole blood and leukocytes as well 
as the TAC-induced effect on calcineurin activity in leukocytes. On the 10 patients 
included in this study, we did not evidence any relation between TAC 
pharmacokinetics (whole blood and leukocytes) and calcineurin activity in leukocytes 
at day 1 and day 7 after the graft implantation. 
 
Capron et al. have recently documented that low TAC concentration in PBMC within 
the first 7 treatment days was associated with the occurrence of ACR in 90 liver 
transplant recipients treated with TAC [10]. However, Capron patients were treated 
with TAC alone whereas our patients received a combination of 3 
immunosuppressive drugs. Different investigations have reported that liver transplant 
recipients experiencing ACR exhibit higher calcineurin activity than those without a 
rejection episode, suggesting a lower pharmacological impact of TAC [16–18]. This 
increased calcineurin activity within a graft rejection episode has also been confirmed 
in patients after lung [35], renal [36] or liver transplantation [18]. The question raised 
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by these studies is: does a low TAC intracellular concentration leading to an 
insufficient inhibition of calcineurin activity may result in the development of ACR ?.  
In accordance with Blanchet et al. [31], the present study failed to find any 
relationship between TAC whole blood pharmacokinetics and calcineurin activity at 
day 7 after liver graft implantation. Interestingly, we show for the first time that TAC 
intracellular exposure was not better correlated with calcineurin activity than TAC 
whole blood exposure. Different reasons can explain this result. Firstly, the 
interindividual variability in calcineurin activity was very large because of both 
analytical reasons [37] and aetiology of liver transplantation [32]. Secondly, the 
profile of calcineurin activity was relatively flat at day 7, probably because our 
patients were exposed to low TAC whole blood concentrations (mean trough 
concentration 5.4 ± 3.1 ng/mL). At saturating TAC concentrations, several in vitro 
studies [38,39] have documented a maximal calcineurin inhibition around 50% for 
tacrolimus-naïve PBMC. This incomplete inhibition of calcineurin activity is related to 
a limited FK Binding Protein 12 amount in cytoplasm [39]. The level of expression of 
other protein, such as FK Binding Protein 13 and FK Binding Protein 25, which binds 
TAC without inhibiting calcineurin activity, might also contributed to the variability in 
calcineurin inhibition in PBMCs [40]. In this context, a high intracellular expression of 
these protein in PBMC could contribute to a lower tacrolimus-induced calcineurin 
inhibition. In liver transplant recipients, Fukudo et al. estimated an EC50 (TAC whole 
blood concentration which decreases maximal calcineurin activity by a half) of 26.4 
ng/mL related to the large diffusion of TAC in erythrocytes [17]. This value of EC50 is 
approximately three-fold higher than the mean TAC whole blood Cmax at day 7 
observed in the present study, which explains in part the modest calcineurin inhibition 
observed over the dosing interval in our study. Thirdly, in contrast with day 7, a 
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significant inhibition of calcineurin activity was observed over the dosing interval at 
day 1 with a nadir 4 hours after TAC intake which corresponds roughly to the whole-
blood and intracellular Cmax. 
 
The interest of the present study also implemented pharmacokinetic and 
pharmacodynamic data in liver transplant recipients exposed to low trough TAC 
whole blood concentrations (target range: 6-10 ng/mL). Indeed, a recent meta-
analysis emphasizes the fact that TAC whole blood trough concentrations maintained 
between 6 and 10 ng/mL in liver transplant recipients during the first month of 
treatment do not lead to a higher rate of ACR when compared with patients in whom 
trough concentrations were between 10 and 15 ng/mL [20]. In the present study, 
baseline calcineurin activity (activity just before the first administration of TAC) and 
trough calcineurin activity at day 7 were not statistically different (655 ± 401 vs 621 
± 469 pmol/min/106 leukocytes, p=0.11). Additionally, only one patient experienced a 
histological ACR episode during the 6-month follow-up (Banff score = 4). Although 
the number of patients included in our study is limited, these results suggest that a 
lack of significant inhibition of calcineurin activity might not cause acute rejection 
when immune systems are suppressed by other drugs such as mycophenolic acid 
and glucocorticoids. Capron et al. have reported a rate of histological ACR around 
40% when TAC is used in monotherapy (target blood concentrations of around 6 
ng/mL) [10]. This result associated with ours suggests that a low CNA inhibition 
should be only targeted when TAC is used in combination with other 
immunosuppressive agents such as mycophenolate mofetil and glucocorticoid.  
However, given that 80% of our patients were transplanted for alcoholic cirrhosis, the 
present results are more specific to these patients which frequently exhibited lower 
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pre-transplantation CNA activity that those observed for other liver aetiologies such 
as viral cirrhosis, autoimmune liver disease [32]. Further investigations with a larger 
cohort including non-alcoholic patients are required to address this issue. Also, 
further pharmacodynamic investigations are necessary to confirm the weak 
calcineurin inhibition at the target range 6-10 ng/mL and its impact on the incidence 
of ACR. 
 
Interestingly, the single patient who experienced ACR during the 6-month follow-up 
exhibited the highest increase in calcineurin activity between day 1 and day 7. 
Despite a good TAC whole blood exposure, this patient had the lowest TAC 
exposure in leukocytes at steady-state because of a very low TAC intracellular ratio, 
which was approximately 6-fold lower than the mean TAC intracellular ratio for the 
patient cohort. In accordance with the work of Capron et al. [10], this episode of ACR 
suggests that monitoring TAC concentration in PBMC may be helpful during the first 
week of treatment to identify patients in whom the TAC intracellular concentration is 
low and therefore the risk of ACR is high. Although this approach seems easier than 
the monitoring of calcineurin activity in daily clinical practice, it cannot take account 
for intracellular factors which can influence calcineurin activity despite a satisfying 
TAC intracellular exposure. These intracellular factors include among others a low 
amount of FK Binding Protein 12 and/or a high amount of FK Binding Protein 13 and 
FK Binding Protein 25 which can bind to TAC without mediating the inhibitory effect 
of TAC on calcineurin [40]. Therefore, monitoring CNA activity would be more 
relevant in daily clinical practice; however one limiting factor to its use is the large 
variability in analytical method related to different factors such as difference in PBMC 
sample composition and loss CNA activity due to fractionizing and separation 
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procedures [37]. In this context, the most powerful and useful tool, between 
intracellular TAC measurement and calcineurin activity monitoring, to identify likely 
non-responders to TAC therapy has yet to be evaluated.     
 
 
5. Conclusion: 
Drug monitoring of TAC intracellular concentrations and determination of the 
calcineurin activity are among future potential biomarkers of acute rejection in 
transplant recipients. A better knowledge of the relationship between TAC whole 
blood and intracellular concentrations and calcineurin activity appears necessary 
before planning clinical trials to evaluate their potential interest as predictive 
biomarkers. The present work highlights new data in liver transplant recipients, in 
particular complete 12-hour pharmacokinetics of intracellular TAC concentrations as 
well as complete profiles of calcineurin activity. 
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Figure legends: 
Figure 1. Mean whole blood tacrolimus concentrations over a 12-hour period in 10 
liver transplant recipients at day-1 (diamonds) and day-7 (squares) after graft 
implantation. Results are expressed as means +/- standard error of the mean. 
 
Figure 2. Mean intracellular tacrolimus concentration over a 12-hour period in 
leukocytes from 10 liver transplant recipients at day-1 (diamonds) and day-7 
(squares) after graft implantation. Results are expressed as means +/- standard error 
of the mean. 
 
Figure 3. Mean calcineurin activity over a 12-hour period in leukocytes from 10 liver 
transplant recipients at day-1 (diamonds) and day-7 (squares) after graft 
implantation. Results are expressed as means +/- standard error of the mean. 
 
Figure 4. Mean whole blood tacrolimus concentrations versus mean intracellular 
tacrolimus concentrations at day-1 (diamonds) and day-7 (squares) after graft 
implantation.  
 
Figure 5. Mean calcineurin activity versus mean intracellular tacrolimus 
concentrations at day-1 (diamonds) and day-7 (squares) after graft implantation.  
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Figure 1.  
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Table 1. Baseline characteristics of the patients. 
  Mean 
Age (year) 56.4 ± 10.9 
Body weight (kg) 69.4 ± 16.6 
Cold ischemia (minutes) 592.4 ± 230.1 
Graft weight (g) 1536.0 ± 482.6 
MELD score 20.4 ± 7.7 
Note: Results are expressed as mean ± SD 
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Table 2. Biological parameters of patients at day-1 and day-7 after graft implantation. 
  
day-1 
 
day-7 
 
p 
Hematocrit (%) 37.5 ± 7.9 
 
28.7 ± 2.9 
 
0.06 
Protein (g/L) 
 
50.7 ± 8.8 
 
 
50.9 ± 8.2 
 
0.36 
Albumin (g/L) 
 
32.4 ± 8.2 
 
 
32.7 ± 2.5 
 
0.94 
Total bilirubin (μmol/L)) 
 
136 ± 161 
 
 
125 ± 126 
 
0.96 
Conjugated bilirubin (μmol/L) 67 ±  74 
 
71 ± 69 
 
0.80 
AST (UI/L) 
 
1181 ± 1456 
 
 
87 ± 92 
 
0.02b 
ALT (UI/L) 
 
738 ± 1021 
 
 
144 ± 117 
 
0.04b 
ALP (UI/L) 
 
107 ± 31 
 
 
170.4 ± 79 
 
0.02b 
Creatinine (μmol/L) 
 
126 ± 88 
 
 
130 ± 93 
 
0.31 
Creatinine clearancea (mL/min) 
 
74.0 ± 27.1 
 
 
74.0 ± 39.1 
 
0.27 
Note: ALP: alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase 
Results are expressed as mean ± SD 
aThe creatinine clearance was estimated using the Modification of Diet in Renal Disease (MDRD) formula 
bStatistically significant result 
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Table 3. Pharmacokinetic parameters for tacrolimus at day-1 and day-7 after graft 
implantation. 
 
  Day-1 Day-7 
Dose (mg/12h) 2.05 ± 0.93 1.67 ± 1.12 
Dose per kg (mg/kg.12h) 0.034 ± 0.012 0.032 ± 0.017 
Blood pharmacokinetics     
Cmax (ng/mL) 13.0 ± 9.6 8.8 ± 5.0 
C12h (ng/mL) 6.9 ± 3.1 5.4 ± 3.1 
AUC0-12 (ng.h/mL) 111.8 ± 65.9 81.2 ± 37.2 
Intracellular pharmacokinetics     
Cmax (pg/million leukocytes) 116.9 ± 114.7 68.3 ± 48.9 
C12h(pg/million leukocytes) 71.3 ± 78.5 39.5 ± 38.8 
AUC0-12 (pg.h/million leukocytes) 909.2 ± 903.7 673.0 ± 602.0 
Intracellular diffusion ratio   
Intracellular AUC0-12 / Whole-blood AUC0-12 40.3 ± 23.3 49.3 ± 45.6 
 
Note: Cmax: maximum concentration over the dosing interval; C12h: concentration measured 12 hours after tacrolimus intake; 
AUC0-12: AUC over the dosing interval 
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Highlights : 
 
 
x The pharmacokinetic-pharmacodynamic relationship of tacrolimus (TAC) 
is detailed 
 
x The first complete intracellular pharmacokinetics of TAC are shown in 
this study 
 
x Interest of monitoring intracellular TAC and/or calcineurin activity is 
suggested 
